PLATFORM Trademark

Trademark Overview


On Wednesday, June 28, 2017, a trademark application was filed for PLATFORM with the United States Patent and Trademark Office. The USPTO has given the PLATFORM trademark a serial number of 87509128. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, October 21, 2020. This trademark is owned by Eli Lilly and Company. The PLATFORM trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations namely, pharmaceutical preparations for the treatment of Alzheimer's disease, anxiety disorders, atopic dermatitis, autoimmune diseases and disorders, axial spondyloarthritis, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythemato...
platform

General Information


Serial Number87509128
Word MarkPLATFORM
Filing DateWednesday, June 28, 2017
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, October 21, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations namely, pharmaceutical preparations for the treatment of Alzheimer's disease, anxiety disorders, atopic dermatitis, autoimmune diseases and disorders, axial spondyloarthritis, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 6, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Thursday, October 22, 2020ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Wednesday, October 21, 2020ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, April 7, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 7, 2020NON-FINAL ACTION E-MAILED
Tuesday, April 7, 2020NON-FINAL ACTION WRITTEN
Thursday, March 12, 2020LIE CHECKED SUSP - TO ATTY FOR ACTION
Wednesday, March 4, 2020ASSIGNED TO LIE
Tuesday, August 13, 2019REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, February 1, 2019REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Wednesday, August 1, 2018NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, August 1, 2018LETTER OF SUSPENSION E-MAILED
Wednesday, August 1, 2018SUSPENSION LETTER WRITTEN
Wednesday, July 25, 2018ASSIGNED TO EXAMINER
Monday, July 2, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, July 2, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 28, 2018TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, April 3, 2018REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Thursday, March 29, 2018ASSIGNED TO LIE
Friday, September 15, 2017NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Friday, September 15, 2017LETTER OF SUSPENSION E-MAILED
Friday, September 15, 2017SUSPENSION LETTER WRITTEN
Thursday, September 14, 2017ASSIGNED TO EXAMINER
Thursday, July 6, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, July 1, 2017NEW APPLICATION ENTERED IN TRAM